Secretome Analysis of an Osteogenic Prostate Tumor Identifies Complex Signaling Networks Mediating Cross-talk of Cancer and Stromal Cells Within the Tumor Microenvironment*
暂无分享,去创建一个
J. Clifton | C. Logothetis | D. Josić | L. Yu-Lee | Sue-Hwa Lin | M. Gajdošík | G. Gallick | S. Maity | Yu‐Chen Lee
[1] N. Itoh,et al. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. , 2011, Journal of biochemistry.
[2] C. Logothetis,et al. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation , 2008, Oncogene.
[3] M. Ittmann,et al. Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression , 2012, Clinical Cancer Research.
[4] M. Mimeault,et al. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine‐1 in cancer , 2010, Journal of cellular physiology.
[5] R. Satcher,et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. , 2011, Cancer research.
[6] P. Russell,et al. Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) Slows Cancer Development but Increases Metastases in TRAMP Prostate Cancer Prone Mice , 2012, PloS one.
[7] M. V. Dinther,et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. , 2008, Kidney international.
[8] E. Vazquez,et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. , 2008, The Journal of clinical investigation.
[9] Payam Shahi,et al. FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. , 2014, Cancer research.
[10] Michael Ittmann,et al. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. , 2013, Cancer research.
[11] M. Ittmann,et al. FGFR1 is essential for prostate cancer progression and metastasis. , 2013, Cancer research.
[12] Tomokazu Fukuda,et al. BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.
[13] S. Aaronson,et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. , 2005, Cancer research.
[14] S. Vukicevic,et al. Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.
[15] S. Batra,et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway , 2010, Oncogene.
[16] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[17] D. El-Rehim,et al. Expression of Macrophage Inhibitory Cytokine-1 in Benign and Malignant Prostatic Tissues: Implications for Prostate Carcinogenesis and Progression of Prostate Cancer , 2010 .
[18] Christine C. Wu,et al. Proteomics of integral membrane proteins--theory and application. , 2007, Chemical reviews.
[19] A. Kozubík,et al. Growth/differentiation factor-15: prostate cancer suppressor or promoter? , 2012, Prostate Cancer and Prostatic Diseases.
[20] Randall T Peterson,et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[21] W. Wood,et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. , 1994, Science.
[22] Brian Bierie,et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.
[23] M. Burdick,et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. , 1999, The American journal of pathology.
[24] Zhen Liu,et al. High-throughput analysis of rat liver plasma membrane proteome by a nonelectrophoretic in-gel tryptic digestion coupled with mass spectrometry identification. , 2008, Journal of proteome research.
[25] M. Reiss,et al. Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.
[26] J. Clifton,et al. Mass spectrometry-based analysis of rat liver and hepatocellular carcinoma Morris hepatoma 7777 plasma membrane proteome. , 2013, Analytical chemistry.
[27] H. Gruber,et al. CXC receptor knockout mice: characterization of skeletal features and membranous bone healing in the adult mouse. , 2011, Bone.
[28] M. Bitzer,et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.
[29] L. Yu-Lee,et al. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts , 2010, Oncogene.
[30] James M. Woolven,et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. , 2006, Journal of medicinal chemistry.
[31] C. Logothetis,et al. Osteoblasts in prostate cancer metastasis to bone , 2005, Nature Reviews Cancer.
[32] Zuxiong Chen,et al. Preferential production of latent transforming growth factor β‐2 by primary prostatic epithelial cells and its activation by prostate‐specific antigen , 2005, Journal of cellular physiology.
[33] A. Jukkola-Vuorinen,et al. Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases , 2007, Cancer Epidemiology Biomarkers & Prevention.
[34] J. Kunz,et al. 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. , 2007, Cancer research.
[35] M. Weller,et al. SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo , 2004, Cancer Research.